Save time and get answers to complex questions with AI chat
How many years does kadcyla's market exclusivity last?Dabrafenib mesylate when the patent is expiring in india?Dabrafenib and trametinib cost?Mobic injection patent oehringer ingelheim france?Drugpatentwatch market analysis industry today?
See the DrugPatentWatch profile for flibanserin
Flibanserin (brand name Addyi) is used to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1].
It is specifically indicated for premenopausal women diagnosed with acquired, generalized HSDD [1].
Flibanserin is not indicated for other populations (such as postmenopausal women) or for sexual desire problems that do not meet the prescription criteria for acquired, generalized HSDD [1].
The medication is intended to help improve sexual desire in women with HSDD as defined in the indication [1].
[1] https://www.drugpatentwatch.com/patent/31745531-flibanserin
Other Questions About Flibanserin :